<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101812</url>
  </required_header>
  <id_info>
    <org_study_id>DMSMIBC-01</org_study_id>
    <nct_id>NCT04101812</nct_id>
  </id_info>
  <brief_title>Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer</brief_title>
  <official_title>A Non-randomized, Prospective Clinical Study of Pegylated Liposomal Doxorubicin and PD-1 in the Second-line Treatment of Relapse or Metastatic Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Pharmaceutical Group Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Second Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite primary surgical management of muscle invasive bladder cancer (MIBC) with radical&#xD;
      cystectomy and pelvic lymphnode dissection, up to 50% of patients will eventually develop&#xD;
      tumours at distant sites, owing to pre-existing disseminated occult micrometastases. The&#xD;
      first line treatment for relapse or metastatic MIBC is gemcitabine and cisplatin. After the&#xD;
      failure of first line treatment, second line chemotherapy drugs can be chosen from&#xD;
      doxorubicin, docetaxel, pemetrexed, etc. This non-randomized, prospective study aims to&#xD;
      explore the efficacy and safety of PEGylated liposomal doxorubicin and PD-1 in second line&#xD;
      treatment of MIBC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at least 10 months</time_frame>
    <description>Disease control rate defined as confirmed complete response or partial response or stable disease under RECIST 1.0 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>at least 10 months</time_frame>
    <description>Objective response rate defined as confirmed complete response or partial response under RECIST 1.0 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at least 10 months</time_frame>
    <description>Progression-free survival estimated using Kaplan-Meier methods is defined as the time from registration to the earlier of death or disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at least 10 months</time_frame>
    <description>Overall survival estimated using Kaplan-Meier methods is defined as the time from treatment initiation to death by any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PD-1 every 3 weeks, for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Doxorubicin Hydrochloride Liposome Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1</intervention_name>
    <description>PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically confirmed muscle-invasive bladder cancer.&#xD;
&#xD;
          -  Histologically confirmed by HE staining or IHC staining.&#xD;
&#xD;
          -  Life expectancy of greater than or equal to 3 months.&#xD;
&#xD;
          -  KPS performance &gt;60, ECOG performance status ≤2.&#xD;
&#xD;
          -  Adequate liver function with a bilirubin up to 1.5 x ULN. Transaminases up to 2.5 x&#xD;
             ULN; for liver metastasis, transaminases up to 5 x ULN.&#xD;
&#xD;
          -  Adequate bone marrow function, as defined by neutrophils count of ≥1.5×109/L, platelet&#xD;
             count≥80×109/L, hemoglobin≥9.0g/dL.&#xD;
&#xD;
          -  Adequate renal function (serum creatinine ≤1.25 times the ULN, and the release rate of&#xD;
             which ≥ 60ml/min).&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          -  Negative serum pregnancy test for female subjects with reproductive potential =&lt; 7&#xD;
             days prior to registration, for women of childbearing potential only. All female&#xD;
             patients of childbearing age and all male patients with partners of childbearing age&#xD;
             should use a reliable method of contraception, such as the barrier method, throughout&#xD;
             the study and for 8 weeks after last treatment.&#xD;
&#xD;
          -  Sign the informed consent before any trial related activities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A prior malignancy, other than non-melanoma skin cancer, carcinoma in situ, localized&#xD;
             prostate cancer or ductal carcinoma in situ treated by surgery unless they have&#xD;
             completed therapy at least 5 years prior to start of study and have no evidence of&#xD;
             recurrent or residual disease&#xD;
&#xD;
          -  Chemotherapy, biological therapy or other anti-cancer drugs ≤ 28 days prior to&#xD;
             pre-registration&#xD;
&#xD;
          -  Factors that would affect taking medicine orally, such as dysphagia, chronic diarrhea&#xD;
             and intestinal obstruction&#xD;
&#xD;
          -  History of arterial/venous thrombus ≤ 6 months prior to registration, such as&#xD;
             cerebrovascular accident, deep vein thrombosis and pulmonary embolism&#xD;
&#xD;
          -  History or tendency of gastrointestinal hemorrhage caused by severe gastroesophageal&#xD;
             varices or other reasons.&#xD;
&#xD;
          -  Dysfunction of blood coagulation: prothrombin time (PT)&gt;16s, activated partial&#xD;
             thromboplastin time (APTT) &gt;43s, thrombin time (TT) &gt;21s, INR &gt;2, fibrinogen &lt; 2g/L,&#xD;
             bleeding tendency or under thrombolytic or anticoagulant therapy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
        ongoing or active infection; poor controlled diabetes (FBG &gt; 10 mmol/L); urine protein ≥++,&#xD;
        and UAE &gt; 1.0g/24h; myocardial ischemia; congestive heart failure; cardiac arrhythmia or&#xD;
        cardiac insufficiency; LVEF &lt; 50%&#xD;
&#xD;
          -  Unhealed wounds, ulcers or fractures&#xD;
&#xD;
          -  Abuse of psychotropic substances or mentally disturbed&#xD;
&#xD;
          -  History of HIV, organ transplantation or any other acquired, congenital&#xD;
             immunodeficiency diseases&#xD;
&#xD;
          -  Patients evaluated not suitable for the study in the opinion of investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haitao Wang</last_name>
    <phone>(022)28331788</phone>
    <email>peterrock2000@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lili Wang</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical Unversity Second Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haitao Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lili Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dingkun Hou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

